TY - JOUR
T1 - Venous thromboembolism characteristics, treatment and outcomes in young adults
T2 - findings from the Registro Informatizado de Enfermedad TromboEmbólica registry
AU - Cohen, Omri
AU - Barg, Assaf A
AU - Nowak-Göttl, Ulrike
AU - Valle, Reina
AU - Mazzolai, Lucia
AU - Tiberio, Gregorio
AU - Schellong, Sebastian
AU - Skride, Andris
AU - Morales, María Del Valle
AU - Monreal, Manuel
AU - Kenet, Gili
AU - RIETE Investigators
A2 - Gibietis, Valdis
A2 - Kigitovica, Dana
N1 - Funding Information:
We express our gratitude to Sanofi Spain and ROVI for supporting this Registry with an unrestricted educational grant. We also thank the RIETE Registry Coordinating Center, S&H Medical Science Service, for their quality control data, logistic and administrative support and Prof. Salvador Ortiz, Universidad Autónoma Madrid, Statistical Advisor in S&H Medical Science Service for the statistical analysis of the data presented in this paper. O.C. M.d.V.M. and G.K. performed study conception and design. All authors interpreted the data. O.C. and G.K. wrote the manuscript. All authors critically revised the manuscript and approved the final version of the article. There are no competing interests to disclose. RIETE is an investigator-initiated registry. It has been previously supported by Red Respira from the Instituto Carlos III, Spain (Red Respira-ISCiii-RTIC-03/11), by Sanofi Spain in Spain and by Bayer Pharma AG for the rest of the world. None of these sponsors have had any role in the design of the registry nor do they have rights to access the database, review or comment on prepublished studies from RIETE. Funding information Registro Informatizado de Enfermedad TromboEmbólica is an investigator-initiated registry previously supported by Red Respira from the Instituto Carlos III, Spain (Red Respira-ISCiii-RTIC-03/11), Sanofi, Spain, and Bayer Pharma AG worldwide. None of these sponsors have had any role in the design of the registry, nor do they have rights to access the database, review, or comment on prepublished studies from Registro Informatizado de Enfermedad TromboEmbólica.
Funding Information:
Funding information Registro Informatizado de Enfermedad TromboEmbólica is an investigator-initiated registry previously supported by Red Respira from the Instituto Carlos III, Spain (Red Respira-ISCiii-RTIC-03/11), Sanofi, Spain, and Bayer Pharma AG worldwide. None of these sponsors have had any role in the design of the registry, nor do they have rights to access the database, review, or comment on prepublished studies from Registro Informatizado de Enfermedad TromboEmbólica.
Publisher Copyright:
© 2023
PY - 2023/7/3
Y1 - 2023/7/3
N2 - BACKGROUND: Venous thromboembolism (VTE) is rare in patients younger than 21 years. Young adults aged 18-21 years are frequently included in adult VTE studies, whereas pediatric VTE studies include patients aged up to either 18 or 21 years. The clinical characteristics of young adult VTE patients have not been well defined.AIM: We aimed to highlight any unique characteristics or treatment considerations that may apply to young adult VTE patients.METHODS: Data from the prospective international RIETE registry were used. Patients were stratified into sub-cohorts according to age. The clinical characteristics, risk factors, management and outcomes of young adult VTE patients were compared with those of adolescents aged 12-18 years and adults older than 21 years.RESULTS: Of 104,253 RIETE patients enrolled until August 2022, 234 were adolescents and 884 young adults. Less cases of pulmonary embolism were reported in adolescents (P < 0.001). Estrogen use was a common risk factor, more prevalent in adolescents and young adults (P < 0.001), whereas active cancer and immobilization were uncommon in either. Most patients were initially treated with low-molecular-weight heparin. VTE recurrence, major bleeding and all-cause mortality rates were comparably low among adolescents and young adults. None of the patients younger than 21 years died from VTE recurrence.CONCLUSION: Young adults have some distinctive VTE risk factors. While VTE presentation may be similar among young adults as compared to older patients, the outcomes of patients younger than 21 years are more favorable.
AB - BACKGROUND: Venous thromboembolism (VTE) is rare in patients younger than 21 years. Young adults aged 18-21 years are frequently included in adult VTE studies, whereas pediatric VTE studies include patients aged up to either 18 or 21 years. The clinical characteristics of young adult VTE patients have not been well defined.AIM: We aimed to highlight any unique characteristics or treatment considerations that may apply to young adult VTE patients.METHODS: Data from the prospective international RIETE registry were used. Patients were stratified into sub-cohorts according to age. The clinical characteristics, risk factors, management and outcomes of young adult VTE patients were compared with those of adolescents aged 12-18 years and adults older than 21 years.RESULTS: Of 104,253 RIETE patients enrolled until August 2022, 234 were adolescents and 884 young adults. Less cases of pulmonary embolism were reported in adolescents (P < 0.001). Estrogen use was a common risk factor, more prevalent in adolescents and young adults (P < 0.001), whereas active cancer and immobilization were uncommon in either. Most patients were initially treated with low-molecular-weight heparin. VTE recurrence, major bleeding and all-cause mortality rates were comparably low among adolescents and young adults. None of the patients younger than 21 years died from VTE recurrence.CONCLUSION: Young adults have some distinctive VTE risk factors. While VTE presentation may be similar among young adults as compared to older patients, the outcomes of patients younger than 21 years are more favorable.
KW - adolescents
KW - anticoagulants
KW - venous thromboembolism
KW - young adults
UR - https://www-webofscience-com.db.rsu.lv/wos/alldb/full-record/MEDLINE:37406932
UR - http://www.scopus.com/inward/record.url?scp=85167782188&partnerID=8YFLogxK
U2 - 10.1016/j.jtha.2023.06.031
DO - 10.1016/j.jtha.2023.06.031
M3 - Article
C2 - 37406932
SN - 1538-7933
JO - Journal of Thrombosis and Haemostasis
JF - Journal of Thrombosis and Haemostasis
ER -
